HK-listed Giant Biogene jumps on share buyback plan
02/12/2025 05:32
** Giant Biogene 2367.HK jumps 6.8% to HK$39.08; on course for biggest one-day pct rise since July 7 ** Stock hits highest since November 17 ** Bioactive material-based beauty and health products developer and maker intends to use own funds to finance share repurchase scheme to reflect its confidence in long-term strategy and growth, while enhancing EPS ** Co, with current market capitalisation of HK$41.4 bln ($5.32 bln), says current share price lower than its intrinsic value and does not fully reflect co's business prospects, asset value ** YTD, stock down 21.7% ($1 = HK$7.7872) (Reporting by Donny Kwok) ((donny.kwok@thomsonreuters.com))
Recent news on Giant Biogene Holding
See all newsGiant Biogene's profit drops on higher distribution expenses
Brief: Giant Biogene Says Cross-Linked Recombinant Collagen Implant Receives China Medical Device Registration Certificate
Brief: Giant Biogene To Distribute Final Dividends Of Rmb0.5390 Per Share
Brief: Giant Biogene's Unit Received NMPA Medical Device Registration Certificate For Recombinant Collagen, Sodium Hyaluronate Solution
HK-listed Giant Biogene jumps on share buyback plan